IMPORTANCE Vascular risk factors are associated with increased risk of Alzheimer disease (AD), but it is unclear whether there is a direct association of these risk factors with AD pathogenesis.
Introduction
The neuropathological hallmarks of Alzheimer disease (AD) include cerebral β-amyloid peptide (Aβ) plaques and hyperphosphorylated tau neurofibrillary tangles. Vascular risk factors, such as dyslipidemia and hypertension, are thought to modify AD risk by promoting both cardiovascular disease and Aβ accumulation. 1 While this dual vascular pathway hypothesis is attractive, results have been mixed. Cholesterol levels and blood pressure (BP) outside of reference ranges, as well as combined vascular risk scores, have been associated with increased Aβ burden in some studies, [2] [3] [4] [5] [6] [7] but other studies have had conflicting results. 8, 9 A few studies also found direct and indirect associations of vascular risk factors with increased tau burden, 8, [10] [11] [12] potentially moderated through Aβ burden; however, a 2009 study 13 did not find these associations.
Such inconsistent results might be explained by potential moderation by vascular medications. 3, 14 Depending on treatment duration and type, 14, 15 the use of statins and antihypertensive drugs may be associated with providing protection against Aβ deposition. 16, 17 Participants using these vascular medications might even have experienced adverse effects of vascular risk factors over many years, but successful treatment preceding data collection could obscure the associations of these vascular risk factors with AD pathogenesis.
We examined whether use of vascular medications moderate the association of vascular risk factors (ie, cholesterol levels, BP, and a combined vascular risk score) with factors associated with AD pathogenesis (ie, Aβ and tau burdens) in middle-to late-aged individuals who were cognitively unimpaired and had a family history of AD. A first-degree family history of AD is associated with a 2to 3-fold increased risk for AD, 18 making individuals with such a family history of AD ideal for studying mechanisms associated with AD at an asymptomatic stage, which is the optimal time for prevention.
Our principal hypothesis was that an association between vascular risk factors and AD pathogenesis would be stronger among individuals who did not use any medications to treat vascular risk factors (untreated cohort) than in individuals using vascular medications (treated cohort).
Methods

Participants and Study Design
Participants were recruited from the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) cohort, an ongoing longitudinal observational study comprising a total sample size of 385 individuals. 19 Inclusion criteria for PREVENT-AD were having parental or multiple-sibling history of AD-like dementia, being 60 years or older at enrollment or age 55 to 59 years if that was fewer than 15 years from the age of symptomatic dementia onset of a sibling or parent, having no major neurological diseases, and having unimpaired cognition. All These cross-sectional analyses considered a subsample of PREVENT-AD participants who had data on Aβ and tau burden, measured by positron emission tomography (PET) or cerebrospinal fluid (CSF) assessment. Analyses were conducted separately in participants who had PET or CSF assessment data. Participants were dichotomized further into those who did not report use of medications to remediate vascular risk factors (untreated cohort) vs those who reported using such medications, including lipid-lowering medications, antihypertensive medications, or both, at enrollment (treated cohort). A joint category of all participants who used vascular medications was created because dyslipidemia and hypertension often co-occur, 23, 24 and vascular medication may act on multiple pathways. 25 All procedures followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines for cross-sectional studies.
This study was approved by the McGill University Faculty of Medicine institutional review board.
All participants received detailed study instructions and gave written informed consent prior to participation. 
Vascular Risk Factor Assessment
Combined Vascular Risk Score
A variety of combined risk scores incorporating multiple vascular risk factors have been previously developed to estimate overall cardiovascular and coronary disease risk with the intent to detect individuals who are at increased risk with greater sensitivity than is possible by assessment of single risk factors. 26 We used the Framingham Coronary Risk Profile (FCRP), a widely used index that estimates 10-year risk of coronary heart disease. 26 The FCRP score is calculated as a sum of weighted measures of age, sex, systolic and diastolic BP, HDL and LDL cholesterol levels, smoking status, and diabetes status. 26 Higher scores indicate greater risk.
Cerebrospinal fluid samples were obtained by lumbar puncture in the morning under fasting conditions. Concentrations of Aβ1-42 and phosphorylated tau (pTau) were measured by enzymelinked immunosorbent assay (INNOTEST; Fujirebio) as described previously. 27 More information about PET and CSF assessment is available in the eAppendix in the Supplement.
PET Processing
Data from PET were preprocessed using a standard pipeline. 28 Briefly, 4-dimensional PET images were calculated for means and linearly coregistered to each individual's T1-weighted images before being masked to exclude CSF binding and smoothed with a 6-mm 3 Gaussian kernel. Individual T1-weighted images were segmented based on the Desikan-Killiany atlas using the semiautomated FreeSurfer processing stream version 5.3 (Martinos Center for Biomedical Imaging). Standardized uptake value ratios (SUVR) were computed for Aβ burden 29 by dividing the tracer uptake by cerebellar gray matter uptake and for tau burden 30 by dividing the tracer uptake by inferior cerebellar gray matter uptake. We restricted the region of interest analyses to FreeSurfer-derived AD-typical regions, in this case, weighted mean SUVRs from the frontal, temporal, parietal, and posterior cingulate cortices for Aβ quantification 29 and from the entorhinal cortex for tau quantification. 31
Genotyping
Genomic DNA was extracted from whole blood, and apolipoprotein E (APOE) genotype was determined using the PyroMark Q96 pyrosequencer (Qiagen), as described previously. 27 Participants were classified as APOE ε4 carriers (ie, those who had 1-2 ε4 alleles) or noncarriers.
Statistical Analysis
Group differences between the treated vs untreated cohorts in the PET and in the CSF assessment groups were tested using unpaired t tests for normally distributed continuous variables, Mann-Whitney U tests for nonnormally distributed continuous variables, or χ 2 tests for categorial variables.
Individuals with missing values were excluded from respective analyses.
To test for the main association of vascular risk factors with AD brain pathogenesis as measured by Aβ or tau deposition, we performed multiple linear regression analyses in untreated and treated cohorts combined. Models included age, sex, vascular medication status (ie, using medication or not), and time difference between vascular risk factor assessments and undergoing PET as
covariates. A second model tested for statistical interaction between vascular risk factors and vascular medication status in association with AD brain pathogenesis, retaining the same covariates as in the first model. Finally, we examined associations of vascular risk factors with AD brain pathogenesis separately for treated and untreated cohorts using independent linear regressions and the same covariates as in the second model. On observing a significant interaction, subgroup analyses were interpreted.
To investigate whether imaging findings could be reproduced using CSF biomarkers, we performed the same multiple regression and within-group analyses using CSF Aβ1-42 and pTau levels as dependent variables. While PET and CSF Aβ and tau biomarkers are known to be correlated, they do not capture the exact same pathological components (soluble vs nonsoluble); thus, PET and CSF may be considered as complementary markers. 32, 33 The mean (range) time delays between assessments of vascular risk factors at enrollment and assessment of Aβ and tau were 45 (3-75) months for participants who underwent PET and 11 (0-62) months for participants who underwent CSF assessment. Vascular risk factors were always assessed prior to PET or CSF assessment. Although we did not expect noteworthy changes in SUVRs as measured by PET within 45 months, 34 we adjusted all statistical models for the time between vascular risk factors and PET or CSF assessment. To explore potential modifying associations of APOE ε4 status, we performed identical analyses that included APOE ε4 status as an additional covariate in the models. Under the assumption that both lipid and BP biomarkers would be associated with AD pathogenesis, we ran an exploratory regression model including both types of risk factors to test whether they were independently associated with AD pathogenesis. Supplementary analyses included linear regression to test whether longer treatment durations for dyslipidemia or hypertension were associated with reduced AD pathological burden. Treatment duration before enrollment in PREVENT-AD was reported by participants through an online questionnaire (response rate, 88%).
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Analyses were performed with SPSS statistical software version 24.0 (IBM Corp). Two-tailed P values less than .05 were considered statistically significant. Analyses were not corrected for multiple comparisons because of complementarity of the vascular risk factor measures. Individual results should therefore be interpreted with caution.
Results
Participant Characteristics
The 
Associations of Vascular Risk Factors With Global Aβ and Entorhinal Tau SUVR Measured by PET
Among participants who underwent PET, no association of vascular risk factors, either as individual factors or combined as FCRP score, was found with global cerebral Aβ deposition. However, interaction analyses showed that among participants not using vascular medications, higher (Figure 1 and Table 2 ).
Specifically, in untreated participants, a 50-mg/dL increase in total cholesterol level was associated with an increase of 0.10 in Aβ SUVR, and a 50-mg/dL increase in LDL cholesterol level was associated with an increase of 0.20 in Aβ SUVR. A 10-mm Hg increase in systolic BP was associated with a 0.06 increase in Aβ SUVR, and a 10-mm Hg increase in pulse pressure was associated with a 0.10 increase in Aβ SUVR. A 1-unit increase in FCRP score was associated with a 0.03 increase in Aβ SUVR. No similar associations were found in the treated cohort of participants who underwent PET. These results remained largely unchanged when APOE ε4 status was added as an additional covariate (eTable 1 in the Supplement). When included in the same regression model, we found independent associations of Aβ burden with LDL cholesterol level (β = 0.003 [SE, 0.001], P = .006) and pulse pressure (β = 0.010 [SE, 0.003], P = .002) in the untreated cohort. Within the treated group, there were no associations of treatment duration with Aβ SUVR after adjusting for age and sex (β = −0.007 [SE, 0.004]; P = .09).
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In contrast to Aβ, there were no main associations of single vascular risk factors with tau deposition, and there were no interactions between single vascular risk factors and vascular medication associated with tau deposition in the entorhinal cortex. An interaction was found between FCRP score and medication use associated with entorhinal tau. Within-group analyses of the treated cohort suggested that a 1-unit increase in the FCRP score was associated with a 0.02 SUVR decrease in entorhinal tau (β = −0.010 [SE, 0.005]; P = .046) ( 
Associations of Vascular Risk Factors With Aβ1-42 and pTau Levels Measured by CSF Assessment
Comparable analyses using CSF assessments found negative associations of lower Aβ1-42 More specifically, a 50-mg/dL increase in LDL cholesterol was associated with a 164-pg/mL decrease in Aβ1-42 levels (thus higher Aβ burden) in the untreated cohort. No significant associations were found between FCRP score and Aβ1-42 in the treated or untreated cohorts. In the treated cohort, we found that a 50-mg/dL increase in HDL cholesterol level was associated with a 393-pg/mL decrease in Aβ1-42, reflecting higher Aβ burden (Figure 2; eTable 3 Discussion This cross-sectional study found that cardiovascular medication use moderated the associations of vascular risk factors with Aβ burden among middle-to late-aged individuals who were cognitively unimpaired but at risk of AD. Specifically, we observed associations of higher total and LDL cholesterol levels, systolic BP, pulse pressure, and a composite of vascular risk factors, FCRP score, with increased cerebral Aβ deposition in individuals who did not use vascular medications.
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Importantly, these associations were not present in individuals who used vascular medications. The associations were not significant when participants were pooled together regardless of their medication status. The findings with LDL cholesterol levels and FCRP score were replicated when Aβ burden was measured using CSF Aβ1-42 levels. We did not observe associations between individual vascular risk factors and cerebral or CSF tau accumulation, but vascular medication use showed an interaction with the association of FCRP score with tau deposition as measured by PET, such that higher FCRP scores were associated with reduced tau deposition in the treated cohort.
While some neuroimaging and autopsy studies have revealed no association of vascular health with Aβ deposition, 8, 35 others have shown detrimental associations of higher cholesterol levels 2 and BP 4, 36 with Aβ accumulation. Our findings may explain these inconsistencies by showing that vascular medication use moderated those associations such that, in our sample, such associations were detectable only in untreated individuals. Similarly, a 2014 study 6 reported that vascular risk factor burden and Aβ were associated with reduced cortical thickness, particularly in individuals who did not use cholesterol-lowering medications, compared with individuals who were treated for hyperlipidemia. Our finding that lipid-lowering and antihypertensive medications moderated the associations of vascular risk factors with Aβ burden could have clinical implications. It has been suggested that cardiovascular medication might reduce AD risk by lowering arterial stiffness, leading to increased cerebral blood flow and Aβ clearance. 16, 37 However, results from a randomized clinical trial 38 and a meta-analysis of cohort studies 39 have been mixed. Other factors, such as treatment duration, participants' age at treatment onset, and medication type, appear to be important to the association of vascular risk factor burden with AD-related end points. 6, 15 Interestingly, the mean Aβ burden was similar in our treated and untreated cohorts. An alternative explanation for why an association of vascular risk factors with Aβ burden was not observed in treated participants might be that vascular risk factors were successfully lowered in most treated participants, but Aβ deposition had started before treatment onset. Figure 1 suggests this, at least with lipid levels: the treated cohort had cholesterol levels within reference ranges, but they may still have experienced adverse effects of their hypercholesterolemia before it was treated. This question may depend also on their medication type, timing, and duration. (age Յ70 years) may be associated with increased AD risk and pathogenesis. 5, 40 Our results from a cohort of participants in middle to late age (mean age, 62 years) support these findings.
Although dyslipidemia and hypertension often co-occur, 23, 24 including both LDL cholesterol level and pulse pressure as factors associated with cerebral Aβ burden in a single regression model did not change our findings, suggesting that these factors were independently associated with the outcome. However, the cross-sectional nature of our analyses makes it possible that the observed associations were inversely related, so that Aβ burden might be associated with altered intracellular vesicle trafficking and metabolic cholesterol homeostasis 41 or vasopressor actions. 42 The strongest known genetic AD risk factor, APOE ε4, has been found to be associated with lipid metabolism, 43 vasculature, 44 Aβ deposition, 45 and moderating the associations of vascular risk factors with AD pathogenesis. 3, 46 However, some studies have reported conflicting results. 7, 8, 40 In our study, associations of vascular risk factors with Aβ burden measured using PET remained after correction for APOE ε4 status, as has been reported previously. 7, 40 However, findings regarding CSF Aβ1-42 levels were only partially independent of APOE ε4 status, suggesting that a potential interaction between genetics and vascular risk factors associated with AD pathogenesis should be further investigated.
It has been argued that composite vascular risk scores are more sensitive measures for detecting associations of vascular risk factors with Aβ burden, 6,7,40 although this has not been consistently confirmed. 12, 47 In our study, the combined FCRP score, LDL cholesterol level, and pulse pressure were the strongest factors associated with presymptomatic AD pathogenesis, but all of these factors had similar associations with Aβ burden, which does not suggest superior sensitivity of the FCRP score compared with single vascular risk factors. One reason for these results might be that our study sample included very few individuals with diabetic comorbidities or smokers, which are both included in the calculation of FCRP score.
With regard to tau, two 2019 studies of older adults who were cognitively unimpaired but who had a mean age 10 years older than participants from the PREVENT-AD cohort reported that higher vascular risk factor burden was associated with increased tau burden in the brain 12 and CSF. 48 We found only 1 interaction between vascular medication use and the FCRP score associated with cerebral tau burden, which unexpectedly suggested that higher vascular risk factor burden was associated with lower tau deposition in the treated cohort. This isolated result could suggest that tau burden is less sensitive to vascular risk factors than Aβ burden and that a combined vascular risk score may be needed to show any association. However, we should note that the levels of cerebral tau in our relatively young cohort were fairly low compared with cerebral Aβ levels; therefore, associations of vascular risk factors and tau burden may have been more difficult to detect.
Furthermore, the association of vascular risk factors with tau was no longer significant when we controlled for APOE ε4 status, drawing into question the strength of this individual association.
Further investigations are needed to better understand whether and how vascular risk factors are associated with tau burden in the early AD continuum, and these inquiries should consider confounding factors, such as medication use.
Strengths and Limitations
Our study has some strengths, including its reliance on middle-to late-aged individuals at risk for AD, thereby perhaps exposing events in the initial accumulation of Aβ burden, that is, a time when vascular risk factors may remain a promising target for disease prevention. The fact that PET findings were substantiated, at least in part, by observations in CSF biomarkers associated with AD lends further credence to the association of vascular risk factors with Aβ burden in such individuals.
Although we adjusted all models for the time difference between assessments of vascular risk factors and assessments of biomarkers associated with AD pathogenesis, the discord in findings with PET and CSF assessment might reflect additional progression of AD stage at the time of PET assessment, 49 which was conducted a mean of 34 months after the CSF assessment. Different PET and CSF findings might also reflect the measurement of different components of Aβ burden. 49 The prevalence of vascular risk factors in our cohort was generally comparable to that of the general US population, 50 except that current smoking status was approximately 10-fold lower in the PREVENT-AD cohort, suggesting that our results are extendible to further populations.
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Our study also has some limitations. We cannot exclude the possibility that participants in the treated cohort may have had healthier lifestyles (eg, more regular exercise, maintaining healthy weight, reduced alcohol consumption and smoking) because of an increased awareness of health concerns.
Such health consciousness may also have influenced our results. Other limitations of the study include its cross-sectional design and that BP values were assessed from only 1 measurement instead of determining a mean of multiple measurements at enrollment. Studies with larger sample sizes are warranted to investigate sex-specific associations of vascular risk factors with AD pathogenesis.
Conclusions
The findings of this cross-sectional study suggest that an individual's use of vascular medications is an important consideration when studying any association of vascular risk factors and AD pathogenesis. Our findings also suggest the importance of targeting both systemic vascular burden and Aβ burden in interventional studies of healthy individuals at risk of AD. Given the current lack of effective AD treatments, the identification of modifiable risk factors associated with development of presymptomatic AD trajectories should be of considerable interest for AD prevention research.
